Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Smita Asare"'
Autor:
Katharine Yu, Amrita Basu, Christina Yau, Denise M. Wolf, Hani Goodarzi, Sourav Bandyopadhyay, James E. Korkola, Gillian L. Hirst, Smita Asare, Angela DeMichele, Nola Hylton, Douglas Yee, Laura Esserman, Laura van ‘t Veer, Marina Sirota
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionDrug resistance is a major obstacle in cancer treatment and can involve a variety of different factors. Identifying effective therapies for drug resistant tumors is integral for improving patient outcomes.MethodsIn this study, we applied
Externí odkaz:
https://doaj.org/article/c9d670c177794b0ba2003ce13caa9f43
Autor:
Hatem Soliman, Denise Wolf, Jo Chien, Christina Yau, Michael Campbell, Mark Magbanua, Ruixiao Lu, Nicholas O'Grady, Lamorna Brown-Swigart, Gillian Hirst, Beverly Parker, Laura Sit, Smita Asare, Doug Yee, Angie DeMichele, Rita Nanda, Lajos Pusztai, Don Berry, Laura Esserman, Laura Van't Veer
Publikováno v:
Cancer Research. 82:PD10-07
Background: The CK12 expression signature consists of genes CCL2, CCL3, CCL4, CCL5, CCL8, CCL18, CCL19, CCL21, CXCL9, CXCL10, CXCL11, CXCL13 and was previously shown to associate with the presence of T and B cell rich tertiary lymphoid structures in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::de80d752234790144d8ce14f93763a74
https://doi.org/10.1158/1538-7445.sabcs21-pd10-07
https://doi.org/10.1158/1538-7445.sabcs21-pd10-07
Autor:
Mark Jesus M. Magbanua, Lamorna Brown Swigart, Ziad Ahmed, Rosalyn W. Sayaman, Derrick Renner, Ekaterina Kalashnikova, Gillian L. Hirst, Christina Yau, Denise M. Wolf, Wen Li, Amy L. Delson, Smita Asare, Minetta C. Liu, Kathy Albain, A. Jo Chien, Andres Forero-Torres, Claudine Isaacs, Rita Nanda, Debu Tripathy, Angel Rodriguez, Himanshu Sethi, Alexey Aleshin, Matthew Rabinowitz, Jane Perlmutter, W. Fraser Symmans, Douglas Yee, Nola M. Hylton, Laura J. Esserman, Angela M. DeMichele, Hope S. Rugo, Laura J. van ’t Veer
Publikováno v:
Cancer Cell.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9f3f5cb5d242c1d2a9b392f722dfcdc6
https://doi.org/10.1016/j.ccell.2023.04.008
https://doi.org/10.1016/j.ccell.2023.04.008
Autor:
Claudine Isaacs, Rita Nanda, Jo Chien, Meghna S. Trivedi, Erica Stringer-Reasor, Christos Vaklavas, Judy C. Boughey, Amy Sanford, Anne Wallace, Amy S. Clark, Alexandra Thomas, Kathy S. Albain, Laura C. Kennedy, Tara B. Sanft, Kevin Kalinsky, Hyo S. Han, Nicole Williams, Mili Arora, Anthony Elias, Carla Falkson, Smita Asare, Ruixiao Lu, Maria Pitsouni, Amy Wilson, Jane Perlmutter, Hope Rugo, Richard Schwab, W. Fraser Symmans, Nola M. Hylton, Laura Van’t Veer, Douglas Yee, Angela DeMichele, Donald Berry, Laura J. Esserman, null I-SPY Investigators
Publikováno v:
Cancer Research. 83:GS5-03
Background: I-SPY2 is a multicenter, phase 2 trial using response-adaptive randomization within biomarker subtypes defined by hormone-receptor (HR), HER2, and MammaPrint (MP) status to evaluate novel agents as neoadjuvant therapy for high-risk breast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c4a5480f0a82171b08b48a2d99c0a033
https://doi.org/10.1158/1538-7445.sabcs22-gs5-03
https://doi.org/10.1158/1538-7445.sabcs22-gs5-03
Autor:
Erica Stringer-Reasor, Rebecca A. Shatsky, Jo Chien, Anne Wallace, Judy C. Boughey, Kathy S. Albain, Hyo S. Han, Rita Nanda, Claudine Isaacs, Kevin Kalinsky, Zahi Mitri, Amy S. Clark, Christos Vaklavas, Alexandra Thomas, Meghna S. Trivedi, Janice Lu, Smita Asare, Ruixiao Lu, Maria Pitsouni, Amy Wilson, Jane Perlmutter, Hope Rugo, Richard Schwab, W. Fraser Symmans, Nola M. Hylton, Laura Van ’t Veer, Douglas Yee, Angela DeMichele, Donald Berry, Laura J. Esserman, I-SPY Investigators
Publikováno v:
Cancer Research. 83:PD11-01
Background: I-SPY2 is a multicenter, phase 2 trial using response-adaptive randomization within biomarker subtypes defined by hormone-receptor (HR), HER2, and MammaPrint (MP) status to evaluate novel agents as neoadjuvant therapy for high-risk breast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::625d2b105ce0db3d41c35f364105e375
https://doi.org/10.1158/1538-7445.sabcs22-pd11-01
https://doi.org/10.1158/1538-7445.sabcs22-pd11-01
Autor:
Amrita Basu, Saumya Umashankar, Michelle Melisko, Ruixiao Lu, Hongmei Yu, Christina Yau, Smita Asare, Maria Pitsouni, Rebecca A. Shatsky, Claudine Isaacs, Angela DeMichele, Dawn Hershman, Rita Nanda, Mi-Ok Kim, Laura J. Esserman, Hope Rugo
Publikováno v:
Cancer Research. 83:GS5-04
Background. Immunotherapy has emerged as an important component of neoadjuvant therapy for some patients with breast cancer (BC). As a result, immune-related adverse events (irAEs) are increasing and have effects on both short and long term symptoms
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::212500da48fe6b404e31fd1a7ea63637
https://doi.org/10.1158/1538-7445.sabcs22-gs5-04
https://doi.org/10.1158/1538-7445.sabcs22-gs5-04
Autor:
Denise M. Wolf, Jane Perlmutter, Judy C. Boughey, A. Jo Chien, Meredith Buxton, Gillian L. Hirst, Douglas Yee, Angela DeMichele, Andres Forero-Torres, Scott M. Berry, Erin D. Ellis, Anthony D. Elias, Julia Wulfkuhle, Michael Alvarado, Christina Yau, Stacy L. Moulder, Nola M. Hylton, Rita Nanda, Amy Wilson, Adam Asare, Debu Tripathy, Claudine Isaacs, Melissa Paoloni, Rosa I. Gallagher, Laura J. Esserman, Richard Schwab, W. Fraser Symmans, Cheryl Ewing, Laura J. van't Veer, Jeffrey B. Matthews, Teresa Helsten, Julia L. Clennell, Barbara Haley, Emanuel F. Petricoin, Katherine Steeg, Smita Asare, Ashish Sanil, Rachel L. Yung, Erin P. Crane, Erin Roesch, Hyo S. Han, Ruby Singhrao, Michelle E. Melisko, Hope S. Rugo, Kathy S. Albain, Donald A. Berry, Anne M. Wallace, Julie E. Lang, Amy S. Clark, Kathleen Kemmer, Lamorna Brown-Swigart
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
Nature communications, vol 12, iss 1
Nature Communications
Nature communications, vol 12, iss 1
Nature Communications
HER2-targeted therapy dramatically improves outcomes in early breast cancer. Here we report the results of two HER2-targeted combinations in the neoadjuvant I-SPY2 phase 2 adaptive platform trial for early breast cancer at high risk of recurrence: ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59a35df0abba974813caa569553019c1
https://doaj.org/article/e6340916dac6476fac8b24ed5afd32c1
https://doaj.org/article/e6340916dac6476fac8b24ed5afd32c1
Autor:
Jane Perlmutter, Janel Hanmer, Barry Dewitt, Aheli Chattopadhyay, Michelle E. Melisko, Amrita Basu, Errol J. Philip, Smita Asare, Laura J. Esserman, Ruby Singhrao, Karyn DiGiorgio, Christina Yau, Adam Asare
Publikováno v:
Cancer Research. 80:P2-12
Background: Breast cancer remains the most frequently diagnosed cancer among women worldwide, accounting for a quarter of all diagnoses. Despite advances in treatment and symptom management, the majority of women will experience some form of drug-rel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4702104928f2948ff048f40a46f46e6a
https://doi.org/10.1158/1538-7445.sabcs19-p2-12-06
https://doi.org/10.1158/1538-7445.sabcs19-p2-12-06
Autor:
Ruby Singhrao, Jane Perlmutter, Angela DeMichele, A. Jo Chien, Christina Yau, HS Han, Donald A. Berry, Patricia A. Robinson, W. Fraser Symmans, Kevin Kalinsky, Laura J. Esserman, Richard Schwab, Anne M. Wallace, Erica Stringer-Reasor, Kathy S. Albain, Patricia K Haugen, Tara Sanft, Amy S. Clark, Ashish Sanil, Smita Asare, Laura J. van't Veer, Kathleen Kemmer, Hope S. Rugo, Amy Wilson, Janice Lu, Julie E. Lang, Minetta C. Liu, Anthony D. Elias, Nola M. Hylton, Rita Nanda, Claudine Isaacs, Douglas Yee, Michelle E. Melisko, Judy C. Boughey
Publikováno v:
Cancer Research. 80:P3-09
Background: I-SPY2 is a multicenter, response-adaptive randomization phase 2 trial to evaluate novel agents when added to standard neoadjuvant therapy for women with high-risk stage II/III breast cancer - weekly paclitaxel + investigational treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e146abf0d3e2626b98c8b19e268a0b28
https://doi.org/10.1158/1538-7445.sabcs19-p3-09-02
https://doi.org/10.1158/1538-7445.sabcs19-p3-09-02
Autor:
HS Han, Christina Yau, Jane Perlmutter, Amy Wilson, Heather Beckwith, Anne M. Wallace, Tara Sanft, Ashish Sanil, Erica Stringer-Reasor, Laura J. Esserman, Zahi Mitri, Donald A. Berry, Rita Nanda, Claudine Isaacs, Alexandra Thomas, Kevin Kalinsky, Hope S. Rugo, Michelle E. Melisko, A. Jo Chien, Smita Asare, W. Fraser Symmans, Judy C. Boughey, Douglas Yee, Laura J. van't Veer, Kathy S. Albain, Amy S. Clark, Julie E. Lang, Anthony D. Elias, Nola M. Hylton, Angela DeMichele, Shi Wei, Richard Schwab
Publikováno v:
Cancer Research. 81:PD1-10
Background: I-SPY 2 is a multicenter, phase 2 trial using response-adaptive randomization within molecular subtypes defined by receptor status and MammaPrint (MP) risk to evaluate novel agents as neoadjuvant therapy for women with high-risk stage II/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::804a4b9c1722f667272e68dbd41f071e
https://doi.org/10.1158/1538-7445.sabcs20-pd1-10
https://doi.org/10.1158/1538-7445.sabcs20-pd1-10